Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
Posted inAlzheimer's Disease Cassava Sciences Inc City University of New York Clinical Trials Dementia Drugs (Pharmaceuticals) Falsification of Data Food and Drug Administration Regulation and Deregulation of Industry Securities and Commodities Violations Securities and Exchange Commission United States Wang, Hoau-Yan

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
F.D.A. Approves a New Antipsychotic Drug
Posted inBristol Myers Squibb Company Clinical Trials Dopamine Drugs (Pharmaceuticals) Food and Drug Administration Karuna Therapeutics Inc Psychiatry and Psychiatrists Psychology and Psychologists Regulation and Deregulation of Industry Research Schizophrenia Therapy and Rehabilitation Weight

F.D.A. Approves a New Antipsychotic Drug

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
Posted inClinical Trials Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychology and Psychologists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.